Identify DNA profiles of multiple cancers with one panel
Efficiently detect single nucleotide variants, copy number variations, insertions and deletions in 460 genes along with microsatellite instability, tumor mutational burden, and homologous recombination deficiency status with targeted NGS relevant for colorectal, breast, melanoma, gastric, pancreatic, CNS, NSCLC, myeloid, lymphoid, and other pan-cancer research.
Detect confidently with Archer VARIANTPlex NGS Panels for DNA.
Learn how the VARIANTPlex Comprehensive Tissue and Blood panel can identify key genomic alterations for your research.
Request a consultationSpecifications | |
---|---|
Targeted genes | 460 |
Genomic alterations | SNVs, Indels, CNVs, ITD, MSI, TMB, HRD |
Input nucleic acid required* | 10 ng |
Recommended number of reads | 61 M |
Hands-on time | <3.5 hours |
Total library prep time | 1.5 days |
Platform compatibility | Illumina® |
Reagent format | Lyophilized or liquid |
Supported sample types | FFPE, fresh froze, cytology smear, FNA |
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50 ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200 ng is recommended.
Customize this NGS panel by adding any of our functionally-tested designs or create a new panel that fits your exact requirements with Assay Marketplace.
Talk with our technical sales team. Learn how the VARIANTPlex Lymphoma panel can identify key genomic alterations for your research.
Request a consultationYes, DNA and RNA from a single sample can be analyzed with VARIANTPlex™ and FUSIONPlex™ panels to provide a genomic profile of the blood cancer. For comprehensive genomic profiling, pair FUSIONPlex Pan Heme and VARIANTPlex Myeloid panels to interrogate 226 genes for fusions, splicing, exon-skipping, SNVs, indels, CNVs, ITDs and expression levels. Additionally, IMMUNOVerse™ assays can provide T- and B-cell clonality, MRD, and somatic hypermutation information relevant for heme malignancies. IMMUNOVerse panels have parallel workflows with VARIANTPlex and FUSIONPlex assays, allowing for comprehensive, streamlined blood cancer profiling.
Yes, minimal residual disease (MRD) / low allele frequency (LAF) can be optimized with VARIANTPlex panels with increased input, using a normalized dataset, increasing the sequencing depth, and using low allelic frequency cycling conditions. For more details on this use, please contact support.
As opposed to traditional priming methods, AMP chemistry enables tiling primers across both strands of DNA, optimally covering targeted regions for amplification and characterization of challenging, yet relevant alterations such as internal tandem duplications. Additionally, AMP chemistry uses molecular barcode adapters that bind to DNA fragments before amplification, allowing for efficient amplification of targets even from degraded or fragmented nucleic acid input, such as DNA from FFPE tissue and ctDNA from plasma.
RUO24-3008_001